Skip to main content
. 2023 Sep 12;18:150. doi: 10.1186/s13014-023-02339-9

Table 5.

Studies on definitive radiotherapy with or without chemotherapy for oesophageal cancer patients

Study Type Pathology Stage N Treatment (n) Radiation dose (Gy) Chemotherapy regimen ORR MST (month) 1 year
OS		 3 year
OS		 5 year
OS
Herskovic A, 1992 [7]; al-Sarraf M, 1997 [8]; Cooper JS, 1999 [6]

Prospective

Randomized

(RTOG 85 − 01)

 Sq/Ad

T1-3

N0-1

M0

 123 RT alone (62) 64 / / 9.3 34% 0% 0%

RT + CT (PF)

(61)

 50

CDDP 75 mg/m2 d1 + 5-FU

1 g/m2/d d1-d4, Q4W

 / 14.1 52% 30% 26%

Minsky

BD, 1996 [30];

Minsky

BD, 1999 [31];

Prospective

(INT 0122)

 Sq

T1-4

N0-1

M0

 38

CT (PF) →

RT + CT (PF)

(38)

 64.8

Neoadjuvant segment:

CDDP 100 mg/m2 d1 + 5-FU 1 g/m2/d d1-d5, Q4W;

Combined segment:

CDDP 75 mg/m2 d1 + 5-FU 1 g/m2/d d1-d5, Q4W

 55% 20 / 30% 20%

Atsushi Ohtsu,

1999 [32]

 Prospective Sq T4/M1 LYM 54

RT + CT (PF)

(54)

 60

CDDP 40 mg/m2 d1, d8 +

5-FU 400 mg/m2/d

d1-d5, d8-d12, Q5W

 87% 9 41% 23% /

Minsky

BD, 2002 [5]

Prospective

(INT 0123)

(RTOG 94 − 05)

 Sq/Ad

T1-4

N0-1

M0

 218

RT + CT (PF)

(109)

 50.4

CDDP 75 mg/m2 d1 + 5-FU

1 g/m2/d d1-d4, Q4W

 / 18.1 40% / /

RT + CT (PF)

(109)

 64

CDDP 75 mg/m2 d1 + 5-FU

1 g/m2/d d1-d4, Q4W

 / 13 31% / /

Ishida K,

2004 [33]

 Prospective Sq T4/M1 LYM 60

RT + CT (PF)

(60)

 60

CDDP 70 mg/m2 d1 + 5-FU

700 mg/m2/d d1-d4, Q4W

 68.3% 10 / / /

Ajani JA,

2008 [34]

Prospective

randomized

(RTOG 0113)

 Sq/Ad Localized 72

CT(TPF) →

RT + CT (TF)

(37)

 50.4 / 28.7 75.7%

CT(TP) →

RT + CT (TP)

(35)

 50.4 / 14.9 68.6%

Li QQ,

2010 [17]

 Retrospective Sq II - IV 59

RT + CT (DP)

(59)

 50–64

CDDP 80 mg/m2 d1 +

Docetaxel 60 mg/m2 d1, Q3W

 98.3% 22.6 / 36.7% /

Kato K,

2011 [35]

Prospective

(JCOG 9906)

 Sq II - III 74

RT + CT (PF)

(74)

 60

CDDP 40 mg/m2 d1, d8 + 

5-FU 400 mg/m2/d

d1-d5, d8-d12, Q5W

 66.2% 29 / 44.7% /
Nishimura Y, 2012 [36]

Prospective

(KROSG0101/

JROSG021)

 Sq/Ad II - IV 91 RT + CT (PF) (46) 60

CDDP 70 mg/m2 d1 + 5-FU

700 mg/m2/d d1-d5, Q4W

 / / / / 35%

RT + CT (PF)

(45)

 60 CDDP 7 mg/m2 d1-d5, d8-d12 + 5-FU 250 mg/m2/d d1-d14, Q4W / / 44% 22% 71%

Zhao T,

2012 [16]

 Prospective Sq II - IV 90

RT + CT (PF)

(45)

 50.4

CDDP 75 mg/m2 d1 + 5-FU

250 mg/m2/d d1-d4, Q4W

 53.3% 22.3 / / /

RT + CT (DP)

(45)

 50.4

CDDP 75 mg/m2 d1 +

Docetaxel 75 mg/m2 d1, Q4W

 73.3% 43.2 / / /

Conroy T,

2014 [3]

Prospective

(PRODIGE5/

ACCORD17)

 Sq/Ad I - IV 267

RT + CT

(FOLFOX)

(134)

 50 / 67% 20.2 19.9%

RT + CT (PF)

(133)

 50

CDDP 75 mg/m2 d1 + 5-FU

1 g/m2/d d1-d4, Q3W/Q4W

 65% 17.5 26.9%

Zhang P,

2016 [37]

 Prospective Sq II - IV 317

RT + CT (PF)

(156)

 50–70

CDDP 60 mg/m2 d1 + 5-FU

300 g/m2 d1-d3, Q4W

 / 24 77.4% 32.8% /

RT + CT (DP)

(161)

 50–70

CDDP 80 mg/m2 d1 +

Docetaxel 60 mg/m2 d1, Q3W;

OR CDDP 25 mg/m2 d1 + Docetaxel 25 mg/m2 d1, QW

 / 21

Dashan Ai,

2022 [10]

Prospective

(ESO-Shanghai2)

 Sq II - IV 321

RT + CT (TP)

(107)

 61.2 CDDP 25 mg/m2/d d1-d3 + Paclitaxel 175 mg/m2 d1, Q4W / / 81.3% 60.1% /

RT + CT (TF)

(107)

 / / / 79.4% 57.2% /

RT + CT (TC)

(107)

 / / / 79.4% 56.5% /
Current study Prospective Sq II - IV 86

RT + CT (DP)

(45)

 55.8–64.0

CDDP 80 mg/m2 d1 +

Docetaxel 60 mg/m2 d1, Q3W

 84.4% 42.27 87.3% 59.5% 52.7%

RT + CT (PF)

(41)

 56.0–64.0

CDDP 80 mg/m2 d1 + 5-FU

1000 g/m2 d1-d4, Q3W

 87.8%

Not

reached

 93.7% 65.5% 62.9%

Abbreviations: Ad = adenocarcinoma; CT = chemotherapy; DP = docetaxel + cisplatin, MST = median survival time; ORR = overall response rate; OS = overall survival; PF = cisplatin + 5-FU; QW = every week; Q3W = every three weeks; Q4W = every four weeks; Q5W = every five weeks; RT = radiotherapy; Sq = squamous cell carcinoma; TP = paclitaxel + cisplatin; TF = paclitaxel + fluorouracil; TC = paclitaxel + carboplatin; TPF = fluorouracil + cisplatin + paclitaxel; FOLFOX = oxaliplatin + leucovorin + fluorouracil.